Format

Send to

Choose Destination
Proteomics Clin Appl. 2007;1(12):1582-1591.

Proteomics studies of pancreatic cancer.

Author information

1
GI Division / Department of Medicine, University of Washington, Seattle, WA 98195.

Abstract

Pancreatic cancer is the fourth leading cause of cancer death in the United States, with 4% survival 5 years after diagnosis. Biomarkers are desperately needed to improve earlier, more curable cancer diagnosis and to develop new effective therapeutic targets. The development of quantitative proteomics technologies in recent years offers great promise for understanding the complex molecular events of tumorigenesis at the protein level, and has stimulated great interest in applying the technology for pancreatic cancer studies. Proteomic studies of pancreatic tissues, juice, serum/plasma, and cell lines have recently attempted to identify differentially expressed proteins in pancreatic cancer to dissect the abnormal signaling pathways underlying oncogenesis, and to detect new biomarkers. It can be expected that the continuing evolution of proteomics technology with better resolution and sensitivity will greatly enhance our capability in combating pancreatic cancer.

Supplemental Content

Full text links

Icon for Wiley Icon for PubMed Central
Loading ...
Support Center